

Continued from previous page...

2) Allocation to Non-Institutional Investors (More than ₹ 10,00,000/-) (After Rejections): The Basis of Allotment to the Non-Institutional Investors, who have bid or above the Offer Price of ₹85.00 per equity shares, was finalized in consultation with BSE. The category was subscribed by 332.19 times i.e. 9,03,56,800 Equity Shares. Total number of shares allotted in this category is 2,72,000 Equity Shares to 56 successful applicants. The category wise details of the Basis of Allotment are as under:

Sr.No	No. of Shares applied for (Category wise)	Number of applications received	% of Total	Total No. of Shares applied in each category	% of Total	No of equity shares Allocated per Applicant	Ratio of allottees to applicants	Total No. of shares allocated/allotted
1	4,800	16,029	91.44	7,69,39,200	85.16	4,800	4: 1233	2,49,600
2	6,400	479	2.73	30,65,600	3.39	6,400	1:479	6,400
3	8,000	207	1.18	16,56,000	1.83	4,800	0:1	-
4	9,600	277	1.58	26,59,200	2.94	4,800	1:277	4,800
5	11,200	539	3.07	60,36,800	6.68	4,800	2:539	9,600
0		1 applicant to be allotted 1600 shares from successful allottees	-	-	-	1,600	1:56	1,600
	TOTAL	17,531	100	9,03,56,800	100.00			2,72,000

3) Allocation to Non-Institutional Investors (More than ₹ 10,00,000/-) (After Rejections): The Basis of Allotment to the Non-Institutional Investors, who have bid or above the Offer Price of ₹85.00 per equity shares, was finalized in consultation with BSE. The category was subscribed by 657.86 times i.e. 35,78,75,200 Equity Shares. Total number of shares allotted in this category is 5,44,000 Equity Shares to 113 successful applicants. The category wise details of the Basis of Allotment are as under:

Sr.No	No. of Shares applied for (Category wise)	Number of applications received	% of Total	Total No. of Shares applied in each category	% of Total	No of equity shares Allocated per Applicant	Ratio of allottees to applicants	Total No. of shares allocated/allotted
1	12,800	26,615	96.99	34,06,72,000	95.21	4,800	22:5323	5,28,000
2	14,400	415	1.51	59,76,000	1.67	4,800	2:415	9,600
3	16,000	158	0.58	25,28,000	0.71	4,800	1:158	4,800
4	17,600	64	0.23	11,26,400	0.31	-	0:1	-
5	19,200	27	0.10	5,18,400	0.14	-	0:1	-
6	20,800	10	0.04	2,08,000	0.06	-	0:1	-
7	22,400	19	0.07	4,25,600	0.12	-	0:1	-
8	24,000	28	0.10	6,72,000	0.19	-	0:1	-
9	25,600	28	0.10	7,16,800	0.20	-	0:1	-
10	27,200	3	0.01	81,600	0.02	-	0:1	-
11	28,800	6	0.02	1,72,800	0.05	-	0:1	-
12	30,400	9	0.03	2,73,600	0.08	-	0:1	-
13	32,000	11	0.04	3,52,000	0.10	-	0:1	-
14	33,600	1	0.00	33,600	0.01	-	0:1	-
15	35,200	3	0.01	1,05,600	0.03	-	0:1	-
16	36,800	1	0.00	36,800	0.01	-	0:1	-
17	38,400	4	0.01	1,53,600	0.04	-	0:1	-
18	40,000	2	0.01	80,000	0.02	-	0:1	-
19	41,600	2	0.01	83,200	0.02	-	0:1	-
20	43,200	2	0.01	86,400	0.02	-	0:1	-
21	46,400	3	0.01	1,39,200	0.04	-	0:1	-
22	48,000	3	0.01	1,44,000	0.04	-	0:1	-
23	49,600	3	0.01	1,48,800	0.04	-	0:1	-
24	51,200	4	0.01	2,04,800	0.06	-	0:1	-
25	52,800	2	0.01	1,05,600	0.03	-	0:1	-
26	54,400	1	0.00	54,400	0.02	-	0:1	-
27	57,600	7	0.03	4,03,200	0.11	-	0:1	-
28	59,200	2	0.01	1,18,400	0.03	-	0:1	-
29	60,800	1	0.00	60,800	0.02	-	0:1	-
30	64,000	1	0.00	64,000	0.02	-	0:1	-
31	67,200	2	0.01	1,34,400	0.04	-	0:1	-
32	76,800	2	0.01	1,53,600	0.04	-	0:1	-
33	83,200	1	0.00	83,200	0.02	-	0:1	-
34	94,400	1	0.00	94,400	0.03	-	0:1	-
35	102,400	4	0.01	4,09,600	0.11	-	0:1	-
36	116,800	1	0.00	1,16,800	0.03	-	0:1	-
37	118,400	1	0.00	1,18,400	0.03	-	0:1	-
38	128,000	2	0.01	2,56,000	0.07	-	0:1	-
39	160,000	1	0.00	1,60,000	0.04	-	0:1	-
40	171,200	1	0.00	1,71,200	0.05	-	0:1	-
41	192,000	1	0.00	1,92,000	0.05	-	0:1	-
42	240,000	1	0.00	2,40,000	0.07	-	0:1	-
0		1 applicant to be allotted 1600 shares from successful allottees	-	-	-	1,600	1:113	1,600
	TOTAL	27,453	100.00	35,78,75,200	100.00			5,44,000

4) Allocation to QIBs excluding Anchor Investors (After Rejections): The Basis of Allotment to the QIBs excluding Anchor Investors, who have bid at the Offer Price of ₹85.00 per equity shares, was finalized in consultation with BSE. The category was subscribed by 148.33 times i.e. 16,13,80,800 Equity Shares. Total number of shares allotted in this category is 10,88,000 Equity Shares to 75 successful applicants. The category wise details of the Basis of Allotment are as under:

Category	FIS/BANK'S	MF'S	IC'S	NBFC'S	AIF	FPI/FPC	Others	TOTAL
QIB	48,000	80,000	6,400	2,57,600	4,46,400	2,49,600	-	10,88,000

5) Allocation to Anchor Investors (After Rejections): The Company in consultation with the BRLM has allotted 16,12,800 Equity Shares to 3 Anchor Investors at Anchor Investor Offer Price of ₹85.00 per equity shares in accordance with the SEBI/ICDR Regulations. The category wise details of the Basis of Allotment are as under:

Category	FIS/BANKS	MF'S	IC'S	NBFC'S	AIF	FPI/FPC	Others	TOTAL
Anchor	-	-	-	-	14,94,400	1,18,400	-	16,12,800

6) Allocation to Market Maker (After Rejections): The Basis of Allotment to Market Maker, who have bid at Offer Price of ₹85.00 per equity shares or above, was finalized in consultation with BSE. The category was subscribed by 1.00 times i.e. for 2,86,400 equity shares. The total number of shares allotted in this category is 2,86,400 Equity Shares. The category wise details of the Basis of Allotment are as under:

No. of Equity Shares Applied for (Category wise)	No. of Applications received	% to total	Total No. of Equity Shares applied in this Category	% of total	No. of Equity Shares allocated/ allotted per Applicant	Ratio	Total Number of shares allotted
2,86,400	1	100.00	2,86,400	100.00	2,86,400	1:1	2,86,400
TOTAL	1	100.00	2,86,400	100.00	2,86,400		2,86,400

The Board of Directors of the Company at its meeting held on October 06, 2026 has approved the Basis of Allocation of Equity Shares as approved by the Designated Stock Exchange viz. BSE and has authorized the corporate action for offer of the Equity Shares to various successful applicants. The CAN-cum-allotment advices and/or notices was forwarded to the email id's of the Applicants as registered with the depositories / as filled in the application form on or before October 07, 2026. Further, the instructions to Self Certified Syndicate Banks for unblocking the amount will process on or before to October 07, 2026. In case the same is not received within ten days, investors may contact at the address given below. The Equity Shares allocated to successful applicants are being credited to their beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is taking steps to get the Equity Shares allotted for trading on the SME platform of BSE Limited within three working days from the date of the closure of the offer.

Note: All capitalized terms used and not defined herein shall have the respective meanings assigned to them in the Prospectus dated October 06, 2026 ("Prospectus") filed with Registrar of Companies, Bangalore.

INVESTORS PLEASE NOTE

The details of the allotment made would also be hosted on the website of the Registrar to the Offer, Maashitla Securities Private Limited at www.maashitla.com . All future correspondence in this regard may kindly be addressed to the Registrar to the Offer quoting full name of the First/ Sole applicants, serial number of the Bid cum Application Form, PAN, Client ID, number of shares applied for and Bank Branch where the application had been lodged and payment details at the address of the Registrar given below:

	Maashitla Securities Private Limited Address: 451, Krishna Apra Business Square, Netaji Subhash Place, Pitampura, New Delhi-110034 Tel: +91-11-47581432 Email: ipo@maashitla.com Website: www.maashitla.com Investor Grievance ID- investor.ipo@maashitla.com Contact Person: Mr. Mukul Agrawal SEBI Registration Number: INR000004370
---	---

For and on behalf EverestIMS Technologies Limited
Sd/-
Satish Kumar Vijayaragavan
Managing Director
DIN: 008080113

Date: October 07, 2026
Place: Bangalore

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF EVERESTIMS TECHNOLOGIES LIMITED.

Disclaimer: EverestIMS Technologies Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares. The Prospectus dated October 06, 2026 has been filed with the Registrar of Companies, Bangalore. The Prospectus is available on the website of BSE at www.bseindia.com, on the website of the BRLM at https://www.oneviewadvisors.com/ and on the website of the Company at https://everestims.com/. Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risk, please see the section entitled "Risk Factors" beginning on page 23 of the Prospectus.

The Equity Shares have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. Accordingly, the Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation "S" under the Securities Act and the applicable laws of each jurisdiction where such offers and sales are made.

IndusInd Bank

IndusInd Bank Limited

CIN: L65191PN1994PLC076333

Registered Office: 2401, Gen. Thimmayya Road (Conment), Pune - 411 001.

Secretarial & Investor Services: 701, Solitaire Corporate Park, 167, Guru Hargovindji Marg, Andheri (East), Mumbai - 400 093.

Tel No.: +91 6641 2487 / 6641 2359 • **Email ID:** investor@indusind.com • **Website:** www.indusind.bank.in

SPECIAL WINDOW FOR RE-LODGE OF TRANSFER REQUESTS OF PHYSICAL SHARES OF INDUSIND BANK LIMITED

Pursuant to earlier, SEBI Circular No.SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97 dated July 2, 2025 and SEBI Circular No. SEBI/HO/38/13/11(2) 2026-MIRSD-POD/II/3750/2026 dated January 30, 2026, all Shareholders of the Bank are hereby informed that a Special Window is open for a period of one year, from February 05, 2026 to February 04, 2027, for re-lodgement of transfer requests of physical shares, which were lodged prior to the deadline of April 1, 2019 and which were rejected / returned / not attended to due to deficiency in the documents / process / or otherwise.

Investors who have missed earlier deadline of March 31, 2021 (the cut-off date for re-lodgement of transfer deeds) & January 06, 2026, are encouraged to take this opportunity by furnishing the necessary documents to the Bank's Registrar and Transfer Agent M/s MUFG Intime India Private Limited (formerly Link Intime India Private Limited), at C-101, 247 Park, LBS Marg, Vikhroli (West), Mumbai - 400 083, Tel.: +91 810811 6767 / 1800 1020 878, e-mail: investor.helpdesk@in.mpmu.mufg.com.

For IndusInd Bank Ltd.
Sd/-
Anand Kumar Das
Company Secretary
Membership No. FCS-6950

Place: Mumbai
Date: October 07, 2026

ONYX BIOTEC LIMITED

CIN: L24230HP2005PLC028403; Website: www.onyxbiotech.com;

Registered Office: Village Bir Plassi, Near Sainimajraropar, Nalagarh Road, Solan- 174101;

Corporate & Marketing Office: S.C.O-70, 2nd Floor, Sector 30-C, Chandigarh- 160030;

Tel. No.: 01795-265363; Fax: 01795-265465; Email: generalinfo@onyxbiotech.com.

Recommendations of the Committee of Independent Directors ("IDC") of Onyx Biotec Limited ("OBL" or the "Target Company") under Regulation 26(7) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and subsequent amendments thereto ["SEBI (SAST) Regulations"] in relation to the Open Offer ("Offer") made by Mr. Kunal Bhardwaj ("Acquirer 1"), Mr. Gautam Bhardwaj ("Acquirer 2"), Mr. Kanhaiya Bhardwaj ("Acquirer 3") and Mr. Kapil Bhardwaj ("Acquirer 4") (hereinafter collectively referred to as the "Acquirers") to the public shareholders of the Target Company under Regulations 3(1) and 4 of the SEBI (SAST) Regulations.

1.	Date	Wednesday, October 07, 2026			
2.	Name of the Target Company	Onyx Biotec Limited			
3.	Details of the Offer pertaining to the Target Company	This Open Offer is being made by the Acquirers for acquisition of upto 47,14,372 (Forty-Seven Lakhs Fourteen Thousand Three Hundred and Seventy-Two) fully paid-up equity shares of the Target Company of Face Value of Rs. 10/- each, representing 26.00% of the total paid-up equity and voting share capital of the Target Company at a price of Rs. 36.50 (Rupees Thirty-Six and Fifty Paise Only) per equity share ("Offer Price"), payable in cash in terms of Regulations 3(1) and 4 of the SEBI (SAST) Regulations. The Public Announcement dated July 24, 2026 ("PA"), Corrigendum to the Public Announcement dated July 30, 2026 ("Corrigendum to the PA"), Detailed Public Statement dated July 31, 2026 ("DPS"), Draft Letter of Offer dated August 07, 2026 ("DLOF") and the Letter of Offer dated September 28, 2026 ("LOF") have been issued by VC Corporate Advisors Private Limited, (being the Manager to the Offer on behalf of the Acquirers).			
4.	Name(s) of the Acquirers and PACs with the Acquirer	1) Mr. Kunal Bhardwaj 2) Mr. Gautam Bhardwaj 3) Mr. Kanhaiya Bhardwaj 4) Mr. Kapil Bhardwaj			
5.	Name of the Manager to the Offer	Name: VC Corporate Advisors Private Limited SEBI Regn No.: INM000011096 Validity of Registration: Permanent CIN: U67120WB2005PTC106051 (Contact Person: Ms. Urvi Belani / Mr. Premjeet Singh) 31, Ganesh Chandra Avenue, 2nd Floor, Suite No.-2C, Kolkata-700 013 Tel. No.: (033) 2225 3940 Email: mail@vccorporate.com Website: www.vccorporate.com			
6.	Members of the Committee of Independent Directors	Sl. No.	Name of Independent Directors	DIN	Designation
		1.	Mr. Nitesh Garg	10257604	Chairperson
		2.	Mr. Vineet Singh	08295419	Member
		3.	Mr. Prince Preet Singh	10716928	Member
7.	IDC Member's relationship with the Target Company (Director, equity shares owned, any other contract / relationship), if any	1. All IDC Members are the Non-Executive & Independent Directors of the Target Company. 2. Neither the Chairperson nor the members of IDC hold any equity shares in Target Company. 3. IDC members have not entered into any contract or have any other relationships with the Target Company except for being Directors of the Target Company.			
8.	Trading in the equity shares /other securities of the Target Company by IDC Members	No trading has been done by the IDC Members in the equity shares/ other securities of the Target Company from the date of Public Announcement till the date of this recommendation.			
9.	IDC Member's relationship with the Acquirers (Director, Equity shares owned, any other contract / relationship), if any.	None of the IDC Members has any relationship with the Acquirers.			
10.	Trading in the equity shares /other securities of the Acquirers by IDC Members	Not Applicable			
11.	Recommendation on the Open offer, as to whether the offer, is or is not, fair and reasonable.	Based on the review of the Public Announcement, Corrigendum to the Public Announcement, the Detailed Public Statement, the Draft Letter of Offer and the Letter of Offer issued by the Manager to the Offer on behalf of the Acquirers, the IDC Members believe that the Open Offer is fair and reasonable.			
12.	Summary of reasons for recommendation	The IDC has taken into consideration the following for making recommendations: IDC has reviewed PA dated July 24, 2026, Corrigendum to the PA dated July 30, 2026, DPS dated July 31, 2026, DLOF dated August 07, 2026 and LOF dated September 28, 2026. The IDC noted that, the Equity Shares of the Target Company are frequently traded within the meaning of the SEBI (SAST) Regulations and that the Offer Price has been determined in accordance with the applicable provisions of the SEBI (SAST) Regulations. The IDC also noted that, as disclosed in the LOF, Ms. Priyanka Singh, Independent Registered Valuer, IBBI Regn.: IBBI/RV/05/2021/14362 vide Valuation Report dated July 24, 2026, bearing Unique Document Identification Number - 26543478GJOB2615, has certified the fair value of equity shares of the Target Company at Rs. 34.51 (Rupees Thirty-Four and Fifty-One Paise Only) per equity share, in accordance with Regulation 8(2) of the SEBI (SAST) Regulations. The IDC further noted the Acquirers are making the Open Offer at an Offer Price of Rs. 36.50 (Rupees Thirty-Six and Fifty Paise Only) per Equity Share, which is higher than the aforesaid fair value determined by the Independent Registered Valuer. The members of the IDC confirm that, as on the date of this recommendation, neither the Target Company nor the Manager to the Offer have received any complaints till date from shareholders in relation to the Open Offer, including with respect to the Offer Price or the valuation methodology adopted. Based on the above, the IDC is of the opinion that as on the date of this recommendation, the Offer Price of Rs. 36.50 (Rupees Thirty-Six and Fifty Paise Only) per equity share offered by the Acquirers to the public shareholders of the Target Company, being higher than the relevant price determined in accordance with the Regulation 8(2) of the SEBI (SAST) Regulations, prima facie appears to be justified. Therefore, IDC recommend acceptance of the Open Offer made by the Acquirers as the Offer Price of Rs. 36.50 (Rupees Thirty-Six and Fifty Paise Only) per fully paid-up equity share is fair and reasonable. However, IDC would like to draw attention of the public shareholders that the equity shares of the Target Company are presently trading on NSE Emerge at a price that is higher than the Offer Price. The IDC further notes that the Equity Shares of the Target Company are presently under Enhanced Surveillance Measures ("ESM"): Stage 1. The public shareholders are advised to independently evaluate the Open Offer via current share price and take an informed decision, before participating in the Open Offer.			
13.	Details of Independent Advisors, if any.	None			
14.	Any other matter to be highlighted	No			

To the best of our knowledge and belief, after making proper enquiry, the information contained in or accompanying this statement is, in all material respect, true and correct and not misleading, whether by omission of any information or otherwise, and includes all the information required to be disclosed by the Target Company under the SEBI (SAST) Regulations.

Capitalized terms used in this announcement, but not defined, shall have the same meaning assigned to them in the PA, Corrigendum to the PA, DPS and the LOF.

For Onyx Biotec Limited
Sd/-
Nitesh Garg
DIN: 10257604
Chairperson - Committee of Independent Directors

Place: Solan
Date: 07.10.2026